| |
Available On-Demand In life sciences today, being able to store, access and use data, no matter where it’s hosted, is crucial. Access this webinar on-demand for an important look at how to make sure the data and applications for critical research work is fully accessible, while also ensuring it is protected and secure. View now. 
|
|
| By Gabrielle Masson The National Institutes of Health has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies. |
|
|
|
By Fraiser Kansteiner After making a pledge on vaccines to Sen. Bill Cassidy during his confirmation process, HHS Secretary Robert F. Kennedy Jr. has promptly reversed course. Now enthroned at the HHS, RFK Jr. has pledged to kick off an investigation into childhood vaccine schedules, mental health medications and more. |
By James Waldron Fierce Biotech recounts the top 10 clinical trial failures of 2024 that sent ripples across the industry. |
By Conor Hale It’s unclear how many staff at the FDA have been affected. There have also been estimates of thousands of dismissals spanning the NIH, the CDC and other agencies across the HHS. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights. 
|
|
By Darren Incorvaia Renee Wegrzyn, Ph.D., the inaugural head of the Advanced Research Projects Agency for Health (ARPA-H), has been let go, a Department of Health and Human Services spokesperson confirmed in an email to Fierce Biotech. |
By Zoey Becker The company's Penmenvy combines components of its established MenB and MenACWY vaccines Bexsero and Menveo, respectively. |
By Kevin Dunleavy The FDA has given a thumbs up to Sanofi’s Merilog as the first biosimilar substitute for Novo Nordisk’s NovoLog for patients with diabetes. It is delivered by a subcutaneous shot 5 to 10 minutes before mealtime to help patients manage glucose and limit blood sugar spikes. |
By Gabrielle Masson Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned. |
By James Waldron A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. |
By Fraiser Kansteiner In 2024’s fourth quarter, Moderna’s cost of sales came out to $739 million, which included a major $238 million charge tied to the cancellation of a contract manufacturing agreement toward the end of the year. |
By Nick Paul Taylor UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake. |
Fierce podcasts Don’t miss an episode |
| Certified community behavioral health clinics, or CCBHCs, provide evidence-based care for mental illness and substance use disorder. There are hundreds of these centers around the U.S. today. |
|
|---|
|
|
|
Tuesday, March 4, 2025 | 2pm ET / 11am PT Learn expert strategies for overcoming the unique challenges of early phase clinical trials, from preparing investigational products to maintaining blinding and sourcing controlled substances. This webinar provides actionable insights to optimize pharmacy activities and ensure trial success. Register now. 
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper There’s so much that goes into making sure your therapy maximizes impact every step of the way. Sponsored by: Accredo By Evernorth |
| Submissions Open Early August |
|
|
| |
|
